Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
HistoIndex, CymaBay collaborate on phase 2 study of seladelpar for NASH
HistoIndex announced a collaboration with CymaBay to evaluate the efficacy of seladelpar for nonalcoholic steatohepatitis in a randomized control phase 2b study using HistoIndex’s Genesis 200 multiphoton digital pathology system, according to a press release.
Diabetes, plasma glucose increases liver disease risk in Chinese patients
Diabetes and high blood glucose levels in individuals without a diabetes diagnosis correlated with increased risks for liver cancer and major chronic liver diseases, according to a large prospective study of Chinese adults.
Log in or Sign up for Free to view tailored content for your specialty!
Ortho Clinical Diagnostics collaborates to promote C-reactive protein assay
Ortho Clinical Diagnostics announced an international distribution and co-promotion agreement with Sentinel Diagnostics to provide the CRP Ultra MicroTip Partnership Assay, a wide-range C-reactive protein assay, according to a press release.
Fibrosis severity determines cause-specific mortality in NAFLD
New data showed that in nonalcoholic fatty liver disease, patients with cirrhosis were more likely to experience liver-related events while those with bridging fibrosis were more likely to experience non-hepatic cancers and vascular events.
CytoSorb receives approval to treat elevated bilirubin in Europe
CytoSorbents received European Union regulatory approval to expand the use of CytoSorb to reduce elevated bilirubin and myoglobin from blood, according to a press release.
New imaging model provides superior fibrosis stage diagnosis
Deep learning radiomics of elastography demonstrated superior predictive value in assessing cirrhosis and advanced fibrosis compared with 2D shear wave elastography and biomarkers among patients with chronic hepatitis B, according to recently published data.
Low subcutaneous adiposity linked to mortality risk in women with cirrhosis
A lower subcutaneous adipose tissue index correlated with higher mortality in women with cirrhosis, while lower skeletal muscle predicted mortality in men with cirrhosis, according to a recently published study.
Conatus completes enrollment in phase 2 trial for NASH cirrhosis inhibitor
Conatus Pharmaceuticals completed enrollment in its ENCORE-PH phase 2 clinical trial for emricasan, an orally-active pan-caspase inhibitor designed to treat nonalcoholic steatohepatitis-related cirrhosis, according to a press release.
Morbid obesity increases risk for acute-on-chronic liver failure
Patients with class III obesity have an increased risk for acute-on-chronic liver failure and a higher prevalence of renal failure as a component of ACLF, according to a recently published study.
Gilead focuses on combination therapy to treat NASH fibrosis
PARIS — In this exclusive interview from the International Liver Congress 2018, Mani Subramanian, PhD, discusses innovative approaches to treating advanced fibrosis in patients with nonalcoholic steatohepatitis.